PMID- 1655221
OWN - NLM
STAT- MEDLINE
DCOM- 19911112
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 68
IP  - 5
DP  - 1991 Sep 1
TI  - Improved survival for children with anaplastic Wilms' tumors.
PG  - 970-4
AB  - Combined modality treatment has resulted in cure rates of approximately 80% for 
      children with Wilms' tumor. According to the National Wilms' Tumor Studies 
      (NWTS), a group of patients with histologic features of anaplasia or sarcomatous 
      Wilms' tumors (malignant rhabdoid tumors and clear cell sarcomas) were less 
      responsive to vincristine and actinomycin. The survival rate of patients in this 
      group with unfavorable histologic conditions was 54% compared with 90% for those 
      with favorable histologic conditions. We have reviewed 80 consecutive cases of 
      Wilms' tumor treated with a minimum follow-up interval of 5 years. Two 
      pathologists independently reviewed all histologic specimens that were initially 
      classified as having unfavorable histologic conditions and specimens from 
      children with favorable histologic conditions who subsequently relapsed. One of 
      13 children with favorable histologic conditions had recurrent disease that was 
      found to have unfavorable histologic conditions on rereview. All five patients 
      with sarcomatous Wilms' tumor had a rapidly progressive course. Treatment of 
      eight children with anaplastic Wilms' tumor with vincristine, actinomycin, 
      cyclophosphamide, and abdominal radiation resulted in good disease-free and 
      overall survival rates (5-year survival rate, 87.5%) that were not significantly 
      different from children with tumors having favorable histologic conditions 
      (5-year survival rate, 94%). All children with sarcomatous histologic conditions, 
      however, did not to respond.
FAU - Corey, S J
AU  - Corey SJ
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
FAU - Andersen, J W
AU  - Andersen JW
FAU - Vawter, G F
AU  - Vawter GF
FAU - Lack, E E
AU  - Lack EE
FAU - Sallan, S E
AU  - Sallan SE
LA  - eng
GR  - 2T32CA09172-12/CA/NCI NIH HHS/United States
GR  - CA-06516/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Carcinoma/drug therapy/*mortality/radiotherapy
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/drug therapy/*mortality/radiotherapy
MH  - Male
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Radiotherapy/adverse effects
MH  - Wilms Tumor/drug therapy/*mortality/radiotherapy
EDAT- 1991/09/01 00:00
MHDA- 1991/09/01 00:01
CRDT- 1991/09/01 00:00
PHST- 1991/09/01 00:00 [pubmed]
PHST- 1991/09/01 00:01 [medline]
PHST- 1991/09/01 00:00 [entrez]
AID - 10.1002/1097-0142(19910901)68:5<970::aid-cncr2820680510>3.0.co;2-5 [doi]
PST - ppublish
SO  - Cancer. 1991 Sep 1;68(5):970-4. doi: 
      10.1002/1097-0142(19910901)68:5<970::aid-cncr2820680510>3.0.co;2-5.